Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Sarcoma 1Other solid neoplasm 1Genitourinary 1Dermatologic 1

Conditions

Lung Neoplasms 28Ovarian Neoplasms 27Fallopian Tube Neoplasms 24Carcinoma, Non-Small-Cell Lung 21Colorectal Neoplasms 17Pancreatic Neoplasms 11Glioblastoma 11Melanoma 10Carcinoma, Renal Cell 10Carcinoma, Hepatocellular 10Breast Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Lymphoma, Large B-Cell, Diffuse 8Urinary Bladder Neoplasms 7Neoplasm Metastasis 7Colonic Neoplasms 7Brenner Tumor 7Uterine Cervical Neoplasms 6Rectal Neoplasms 6Prostatic Neoplasms 6Mycosis Fungoides 6Leukemia, Lymphocytic, Chronic, B-Cell 6Brain Neoplasms 6Triple Negative Breast Neoplasms 5Multiple Myeloma 5Lymphoma, T-Cell, Cutaneous 5Sezary Syndrome 4Sarcoma 4Neoplasms 4Nasopharyngeal Carcinoma 4

Interventions

Taxes 2Immunoglobulin G 2Disulfides 2Bevacizumab 2pembrolizumab 1Yoga 1Specimen Handling 1Sentinel Lymph Node Biopsy 1Salpingo-oophorectomy 1Radiation 1Platinum 1Paclitaxel 1Congresses as Topic 1Cisplatin 1Brachytherapy 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Cervical Adenocarcinoma × Disulfides × Clear all
NCT06543576 2025-08-15

External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer

Jonsson Comprehensive Cancer Center

Phase 1/2 Recruiting
35 enrolled
Gynecologic

Cervical Adenocarcinoma

NCT02020707 2024-07-26

Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers

Mayo Clinic

Phase 1 Completed
43 enrolled
DermatologicGenitourinaryGynecologicOther solid neoplasmSarcoma

Cervical Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡